Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

Instability of immunophenotype in plasma cell myeloma.

Cao W, Goolsby CL, Nelson BP, Singhal S, Mehta J, Peterson LC.

Am J Clin Pathol. 2008 Jun;129(6):926-33. doi: 10.1309/8UVF7YQ1D4D4ETQV.

PMID:
18480010
2.

Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.

Lin P, Owens R, Tricot G, Wilson CS.

Am J Clin Pathol. 2004 Apr;121(4):482-8.

PMID:
15080299
3.

Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.

Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P.

Am J Clin Pathol. 2009 Nov;132(5):728-32. doi: 10.1309/AJCP1GYI7EHQYUYK.

PMID:
19846814
5.

Four-color flow cytometric analysis of myeloma plasma cells.

Kobayashi S, Hyo R, Amitani Y, Tanaka M, Hashimoto C, Sakai R, Tamura T, Motomura S, Maruta A.

Am J Clin Pathol. 2006 Dec;126(6):908-15.

PMID:
17153775
6.

Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.

Leo R, Boeker M, Peest D, Hein R, Bartl R, Gessner JE, Selbach J, Wacker G, Deicher H.

Ann Hematol. 1992 Mar;64(3):132-9.

PMID:
1373957
8.

Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.

Rigolin GM, Tieghi A, Ciccone M, Bragotti LZ, Cavazzini F, Della Porta M, Castagnari B, Carroccia R, Guerra G, Cuneo A, Castoldi G.

Br J Haematol. 2003 Mar;120(6):953-9.

PMID:
12648064
9.

Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.

Liu D, Lin P, Hu Y, Zhou Y, Tang G, Powers L, Medeiros LJ, Jorgensen JL, Wang SA.

J Clin Pathol. 2012 Sep;65(9):823-9. doi: 10.1136/jclinpath-2012-200881. Epub 2012 Jun 8.

PMID:
22685235
10.

Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma.

Harrington AM, Hari P, Kroft SH.

Am J Clin Pathol. 2009 Jul;132(1):60-6. doi: 10.1309/AJCPOP7TQ3VHHKPC.

PMID:
19864234
11.

[Immunophenotypic characteristics of multiple myeloma cells].

Li JL, Liu YR, Chang Y, Fu JY, Chen SS.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2002 Jun;10(3):226-8. Chinese.

PMID:
12513791
12.

Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia.

Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED.

Mod Pathol. 2009 Jun;22(6):807-16. doi: 10.1038/modpathol.2009.34. Epub 2009 Mar 13.

13.

The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome.

Ngo NT, Brodie C, Giles C, Horncastle D, Klammer M, Lampert IA, Rahemtulla A, Naresh KN.

J Clin Pathol. 2009 Nov;62(11):1009-15. doi: 10.1136/jcp.2009.065128.

PMID:
19861559
15.

Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.

San Miguel JF, González M, Gascón A, Moro MJ, Hernández JM, Ortega F, Jimenez R, Guerras L, Romero M, Casanova F, et al.

Br J Haematol. 1991 Feb;77(2):185-90.

PMID:
1706197
16.

The incidence of DNA aneuploidy in multiple myeloma does not correlate with stage of disease.

Nowak R, Oelschlägel U, Range U, Mölle M, Ehninger G.

Am J Clin Pathol. 1998 Feb;109(2):226-32.

PMID:
9583896
17.

Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma.

Dahl IM, Rasmussen T, Kauric G, Husebekk A.

Br J Haematol. 2002 Feb;116(2):273-7.

PMID:
11841427
18.

Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.

Rawstron A, Barrans S, Blythe D, Davies F, English A, Pratt G, Child A, Morgan G, Jack A.

Br J Haematol. 1999 Jan;104(1):138-43.

PMID:
10027726
19.

Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry.

Bozzi F, Gambirasio F, Luksch R, Collini P, Brando B, Fossati-Bellani F.

Anticancer Res. 2006 Sep-Oct;26(5A):3281-7.

Supplemental Content

Support Center